Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06826196 · ClinicalTrials.gov registry record · Phase 1
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALD-102 Solution in Subjects With Alopecia Areata
A Phase 1 study of Alopecia Areata (AA), sponsored by Aldena Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 7
- Study locations
NCT06826196: Recruiting Phase 1 study of Alopecia Areata (AA), sponsored by Aldena Therapeutics.
NCT06826196 is a Phase 1 study of Alopecia Areata (AA) that is actively recruiting participants, run by Aldena Therapeutics. The registered enrollment target is 24 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (60% lower). The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06826196, a Phase 1 study of Alopecia Areata (AA), is actively recruiting participants, sponsored by Aldena Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 7
- Study locations
Study Summary
The goal of this first-in-human clinical trial is to learn if ALD-102 Solution is safe and well tolerated following injections in the scalp in subjects with alopecia areata. The study will also learn about the effect of ALD-102 on hair regrowth in treatment areas. The researchers will compare the effects of ALD-102 Solution (drug) to placebo (saline solution that contains no drug) or an untreated area. Study participants will have treatment areas selected on the scalp to receive ALD-102 Solution (drug), placebo (saline solution) or to remain untreated. Injections will occur once every 4 weeks for a treatment period of 8 weeks.
Primary Outcome
AEs assessed by guidelines outlined in CTCAE at baseline, during treatment and follow-up periods. ISRs assessed by local tolerability assessments (LTA), including evaluation by the investigator of erythema, swelling, induration, and bruising, and evaluation by the subject of burning, stinging and itching. Grading using a 4-point scale of 0 to 3 (non, mild, moderate, severe) will be used to assess each sign. Pain at each treatment area will also be assessed using a pain numerical rating scale (NR
Conditions Studied
Interventions
- DRUG ALD-102 Solution
- OTHER Placebo or Control
Study Locations (7)
Quebec
- Innovaderm - Montreal
- Centre de Recherche Saint-Louis - Québec
California
- Clinical Trial Research Institute - Thousand Oaks
Indiana
- Options Research Group - West Lafayette
Massachusetts
- The Brigham and Women's Hospital - Boston
Washington
- Dermatology Specialists of Spokane - Spokane
Ontario
- The Centre for Clinical Trials - Oakville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2025-03-24 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
What NCT06826196 shows while recruiting
NCT06826196 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (60% lower).
The record links to 1 condition, with Alopecia Areata (AA) appearing as the primary indexed condition, and to 2 interventions - of which ALD-102 Solution is the first listed.
NCT06826196 lists 7 locations in 6 states (Quebec, California, Indiana).
Frequently Asked Questions
What is clinical trial NCT06826196 about?
NCT06826196 is a clinical study titled "A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALD-102 Solution in Subjects With Alopecia Areata". The goal of this first-in-human clinical trial is to learn if ALD-102 Solution is safe and well tolerated following injections in the scalp in subjects with alopecia areata. The study will also learn about the effect of ALD-102 on hair regrowth in treatment areas. The researchers will compare the ef...
What is the current status of trial NCT06826196?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2025-03-24. Estimated completion is 2026-12.
What conditions does trial NCT06826196 study?
This clinical trial studies the following conditions: Alopecia Areata (AA).
What interventions are being tested in trial NCT06826196?
The interventions under investigation include: ALD-102 Solution (DRUG), Placebo or Control (OTHER).
Who is sponsoring clinical trial NCT06826196?
This trial is sponsored by Aldena Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06826196 being conducted?
This trial has 7 study locations across California, Indiana, Massachusetts, Washington, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alopecia Areata (AA)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06826196's enrollment target sits among peer trials
24 1521st of 2000 higher than 405 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI